BR112022018136A2 - Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização - Google Patents

Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização

Info

Publication number
BR112022018136A2
BR112022018136A2 BR112022018136A BR112022018136A BR112022018136A2 BR 112022018136 A2 BR112022018136 A2 BR 112022018136A2 BR 112022018136 A BR112022018136 A BR 112022018136A BR 112022018136 A BR112022018136 A BR 112022018136A BR 112022018136 A2 BR112022018136 A2 BR 112022018136A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
hemorrhage
thrombolytic drug
reperfusion injuries
Prior art date
Application number
BR112022018136A
Other languages
English (en)
Portuguese (pt)
Inventor
Joo Gwag Byoung
San An Chun
yu jin Jing
Ig Cho Sung
Zhu Fangmeng
Xu Xinliang
Zhan Weiqiang
Liu Fuxin
Won Soon-Mi
Original Assignee
Gnt Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnt Pharma Co Ltd filed Critical Gnt Pharma Co Ltd
Publication of BR112022018136A2 publication Critical patent/BR112022018136A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112022018136A 2020-03-11 2021-03-10 Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização BR112022018136A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (1)

Publication Number Publication Date
BR112022018136A2 true BR112022018136A2 (pt) 2022-10-25

Family

ID=77665492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018136A BR112022018136A2 (pt) 2020-03-11 2021-03-10 Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização

Country Status (12)

Country Link
US (3) US11826329B2 (https=)
EP (1) EP4117648A4 (https=)
JP (1) JP2023517566A (https=)
KR (1) KR20230010187A (https=)
CN (1) CN115515573A (https=)
AU (1) AU2021233206A1 (https=)
BR (1) BR112022018136A2 (https=)
CA (1) CA3174709A1 (https=)
CO (1) CO2022014343A2 (https=)
IL (2) IL296288B2 (https=)
MX (2) MX2022011214A (https=)
WO (1) WO2021181159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
CN113995723B (zh) * 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
KR20240142433A (ko) * 2021-12-28 2024-09-30 주식회사 지엔티파마 폐 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309703C (zh) * 2002-06-19 2007-04-11 纽若泰克有限公司 四氟苄基衍生物及含有其成分的用于治疗和预防中枢神经系统的急慢性神经变性疾病的药物组合物
KR100522188B1 (ko) * 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
WO2006126825A1 (en) 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
CN101180263B (zh) 2005-05-25 2011-11-02 株式会社中外制药 取代四氟苄基苯胺化合物及其药学可接受的盐的制备方法
KR101523345B1 (ko) 2008-04-28 2015-05-28 주식회사 지엔티파마 재관류 손상의 치료 또는 예방용 약학 조성물
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
JP2018502894A (ja) 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Also Published As

Publication number Publication date
EP4117648A1 (en) 2023-01-18
EP4117648A4 (en) 2024-05-29
US12433861B2 (en) 2025-10-07
KR20230010187A (ko) 2023-01-18
IL296288B1 (en) 2024-02-01
US20260027076A1 (en) 2026-01-29
US20230390231A1 (en) 2023-12-07
JP2023517566A (ja) 2023-04-26
US20210283080A1 (en) 2021-09-16
IL309923A (en) 2024-03-01
IL296288A (en) 2022-11-01
US11826329B2 (en) 2023-11-28
WO2021181159A1 (en) 2021-09-16
MX2022011214A (es) 2022-10-07
CO2022014343A2 (es) 2023-02-16
AU2021233206A1 (en) 2022-10-06
CN115515573A (zh) 2022-12-23
IL296288B2 (en) 2024-06-01
MX2025012439A (es) 2025-11-03
CA3174709A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
BR112022018136A2 (pt) Composições e métodos para tratar lesões de reperfusão ou hemorragia após terapia de recanalização
US20080279896A1 (en) Treatment of movement disorders by a combined use of chemodenervating agent and automated movement therapy
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
López-López et al. Application of cantharidin, podophyllotoxin, and salicylic acid in recalcitrant plantar warts. A preliminary study
EP4483955A3 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
Aguilera-Roig et al. Tranexamic acid in orthopedic surgery
KR20040014459A (ko) 탈수초성 질병 또는 상태의 치료방법
Zeng et al. Activation of inflammasomes and relevant modulators for the treatment of microglia-mediated neuroinflammation in ischemic stroke
AU2014210332B2 (en) Method of treating fibrosis in skeletal muscle tissue
RU2417765C2 (ru) Способ лечения подкожной гематомы, образовавшейся вследствие укуса животного
NADERI et al. The effectiveness of ozone therapy in chronic osteomyelitis: A randomized controlled clinical trial
Sonune et al. Comparative study of ultrasound guided supra-scapular nerve block versus intra-articular steroid injection in frozen shoulder
Kurt et al. Effects of adding alfentanil or atracurium to lidocaine solution for intravenous regional anaesthesia
Su et al. Comparison between periarticular analgesia versus intraarticular injection for effectiveness and safety after total knee arthroplasty
CR20250205A (es) Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il) butan-2-il) benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus.
CA2785303A1 (en) Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual
Srivastava et al. A comparative Clinical Study of Intrathecal Ropivacaine and Ropivacaine-clonidine combination for lower limb orthopaedic surgeries
RU2548739C1 (ru) Способ лечения реперфузионного синдрома у больных сахарным диабетом после реваскуляризирующих операций на артериях нижних конечностей
Jadhav et al. A prospective, multicentric study to determine the safety and effectiveness of fixed-dose combination of camylofin dihydrochloride and nimesulide in patients presenting with acute colicky abdominal pain in India
CY1113544T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος
Utomo et al. Potentials of tranexamic acid injection to reduce bleeding in patients of total knee replacement procedure
TW202615093A (zh) 再使用於已中止免疫檢查點抑制劑給藥之癌症患者之免疫檢查點抑制劑的治療效果提高用醫藥
Cengiz et al. Bleeding and Clotting Control in ACL Reconstruction

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025026201-3 PROTOCOLO 870250109070 EM 27/11/2025 17:53.